RDHL vs. IMNN, MIRA, PPBT, TNXP, AVTX, NNVC, TRAW, MNPR, ABVC, and EDSA
Should you be buying RedHill Biopharma stock or one of its competitors? The main competitors of RedHill Biopharma include Imunon (IMNN), MIRA Pharmaceuticals (MIRA), Purple Biotech (PPBT), Tonix Pharmaceuticals (TNXP), Avalo Therapeutics (AVTX), NanoViricides (NNVC), Traws Pharma (TRAW), Monopar Therapeutics (MNPR), ABVC BioPharma (ABVC), and Edesa Biotech (EDSA). These companies are all part of the "pharmaceutical preparations" industry.
RedHill Biopharma (NASDAQ:RDHL) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.
Imunon has a consensus price target of $13.00, suggesting a potential upside of 892.37%. Given Imunon's higher probable upside, analysts plainly believe Imunon is more favorable than RedHill Biopharma.
RedHill Biopharma received 419 more outperform votes than Imunon when rated by MarketBeat users. However, 100.00% of users gave Imunon an outperform vote while only 69.09% of users gave RedHill Biopharma an outperform vote.
RedHill Biopharma has higher revenue and earnings than Imunon.
In the previous week, RedHill Biopharma had 1 more articles in the media than Imunon. MarketBeat recorded 2 mentions for RedHill Biopharma and 1 mentions for Imunon. RedHill Biopharma's average media sentiment score of 0.30 beat Imunon's score of 0.00 indicating that RedHill Biopharma is being referred to more favorably in the media.
7.2% of RedHill Biopharma shares are held by institutional investors. Comparatively, 4.5% of Imunon shares are held by institutional investors. 6.8% of RedHill Biopharma shares are held by insiders. Comparatively, 3.8% of Imunon shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
RedHill Biopharma has a beta of 3.47, suggesting that its stock price is 247% more volatile than the S&P 500. Comparatively, Imunon has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500.
RedHill Biopharma's return on equity of 0.00% beat Imunon's return on equity.
Summary
RedHill Biopharma beats Imunon on 10 of the 14 factors compared between the two stocks.
Get RedHill Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RDHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RedHill Biopharma Competitors List
Related Companies and Tools
